TEMHIGH SIGNALOPERATIONAL10-K

TEM underwent a significant business transformation with substantially expanded revenue and a major organizational restructuring from three to two product lines.

The company appears to have executed a major strategic pivot or acquisition, given the substantial revenue growth and complete reorganization of its business structure. The shift from three product lines (Genomics, Data, AI Applications) to two (Diagnostics, Data and applications) suggests a consolidation strategy focused on core competencies in healthcare data and diagnostics.

Comparing 2026-02-24 vs 2025-02-24View on EDGAR →
FINANCIAL ANALYSIS

TEM's financial profile transformed dramatically with revenue roughly doubling to $1.3B while operating losses were meaningfully reduced from $691M to $253M. The company significantly strengthened its balance sheet with cash reserves growing from $341M to $605M, though operating cash flow remained negative at $218M. Despite the substantial revenue expansion, R&D expenses grew modestly at 16%, suggesting improved operational leverage in the business model.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+83.4%
$693.4M$1.3B

Strong top-line growth of 83.4% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
+77.4%
$341.0M$604.8M

Cash position surged 77.4% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+74.8%
$667.6M$1.2B

Current assets grew 74.8% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
+65.3%
-$705.8M-$245.0M

Net income grew 65.3% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+63.4%
-$691.1M-$252.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
+34.7%
$38.4M$51.7M

Inventory surged 34.7% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Liabilities
Balance Sheet
+27.9%
$291.1M$372.4M

Current liabilities rose 27.9% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
+15.8%
$149.3M$172.9M

R&D investment increased 15.8% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
-15.4%
-$189.0M-$218.1M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-24
ADDED
As of February 20, 2026, there were 173,729,901 shares of Class A common stock and 5,043,789 shares of Class B common stock, each with a par value of $0.0001 per share, outstanding.
Our Platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions through more than 700 unique data connections, many of which supply us with complex multimodal data in near real time, across more than 5,000 healthcare institution sites that order our products and services.
Our products are organized under two product lines, Diagnostics , which comprises our Oncology and Hereditary testing businesses, among others, and Data and applications , which includes, our Insights, Next, Trials and Algos businesses, among others .
Our Data and applications product line facilitates drug discovery and development for life sciences companies through multiple products, including, among other things, Insights, Trials, Next and Algos.
Our Trials product leverages the broad network of physicians we work with in oncology to provide clinical trial support for pharmaceutical companies that are looking to reach hard-to-find and underserved patient populations.
+7 more — sign up free →
REMOVED
As of February 21, 2025, there were 167,168,911 shares of Class A common stock and 5,043,789 shares of Class B common stock, each with a par value of $0.0001 per share, outstanding.
3 Our Platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions through approximately 700 unique data connections, many of which supply us with complex multimodal data in near real time, across approximately 3,000 healthcare institutions that order our products and services.
Our products are organized under three product lines, Genomics , Data , and AI Applications or Algos.
Our Data and Services product line facilitates drug discovery and development for life sciences companies through two primary products, Insights and Trials.
Our second product within our Data and Services product line, Trials , leverages the broad network of physicians we work with in oncology to provide clinical trial support for pharmaceutical companies that are looking to reach hard-to-find and underserved patient populations.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →